TCL Archive Managed Care: Cancer Panel Finds Need “Critical” For Cost, Outcomes Data September 13, 1996
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive De-Emphasis of Tradition Grants Still Haunts Some; “Recent NCI Actions Held Up As Evidence May 21, 1976
TCL Archive In Brief: Fishman La Jolla President Emeritus, Ruoslahti Succeeds Him; Ariz. Seeks Meyskins Replacement January 13, 1989